FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Ex-FDA Lawyer Temkin Joins Paul Hastings

[ Price : $8.95]

Former FDA associate chief counsel and CDER policy advisor Eva A. Temkin joins Paul Hastings as chair of the firms FDA practice.

Vyaire Recalls Airlife Resuscitator

[ Price : $8.95]

Vyaire Medical recalls its AirLife Adult Manual Resuscitator and oxygen reservoir bag due to out-of-specification components used ...

Milestone Pharma Refiling Etrpamil NDA

[ Price : $8.95]

After receiving a 12/2023 FDA refuse-to-file letter, Milestone Pharmaceuticals now says it will resubmit the NDA in the second qua...

Animal Drug Regs Amended to Reflect Approvals

[ Price : $8.95]

Federal Register notice: FDA amends its animal drug regulations to reflect application-related actions animal drug applications ap...

Boehringer Reports Gains on Liver Disease Candidate

[ Price : $8.95]

Boehringer Ingelheim reports data from its Phase 2 survodutide study showing that up to 83.0% of adults treated with the drug achi...

After 2 Earlier Denials, Humira Biosimilar OKd

[ Price : $8.95]

FDA approves Alvotech and Teva Pharmaceuticals Simlandi (adalimumab-ryvk) injection, an interchangeable biosimilar to AbbVies Humi...

Rybrevants Regulatory Review Period Determined

[ Price : $8.95]

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Janssen Biotechs Rybrevant ...

New App for Reporting Drug Amounts Produced

[ Price : $8.95]

FDA creates a new CARES Act Amount Information Reporting application for drug establishments to use when submitting (xxx insert, d...

NY Attorney General Urges FDA Action on Singulair

[ Price : $8.95]

New York attorney general Letitia James urges FDA to take further safety actions to address the dangers of Mercks Singilair (monte...

BrainStorm Seeks Special Protocol for ALS Treatment

[ Price : $8.95]

BrainStorm Cell Therapeutics files a Special Protocol Assessment request for a Phase 3b study of NurOwn, its investigational treat...